



## **We Value the Contribution of Our Current and Future Strategic Partners**

Oncotherapy Solutions, LLC will be financially stable and viable through two strategic decisions: The initial phase will depend on SBIR grants from the National Cancer Institute and from private investors. The second phase will depend on Licensing & Partnerships with other biotech and pharmaceutical companies as well as from product sales.

The company is seeking pharmaceutical and biotechnology partners to work with to advance its preclinical programs and move lead drug conjugates to clinical trials. Our drug conjugates are stable, potent and safer than standard of care.

Oncotherapy Solutions, LLC will be out-licensing some of its drug conjugates to interested biotechnology and pharmaceutical companies. Our company has many appealing characteristics as compared to other biotech companies:

- Our business strategy is to stay small but efficient and competitive which will allow us to save our resources and direct them toward our three preclinical programs.
- Management has tremendous previous experience in drug development and drug delivery, having previously worked on drug candidates that are currently in the market or in late clinical trials.
- Management has strong background in biotech project management and business administration as well as excellent publication record and patent portfolio.
- Our 2 preclinical programs are carefully-designed and our drug conjugates have a great potential in reaching the market.